A5314: Effect of LDMTX on Inflammation in HIV-infected Individuals

Study Location:

Baltimore

Topic:

HIVCardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT01949116?term=a5314&rank=2

IRB#:

NA_00088694

Coordinator:

Ilene Wiggins, RN

Enrollment:

Closed

Trial Period:

Completed

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of LDMTX on endothelial function and inflammation in virologically suppressed HIV-infected participants.

HIV-infected men and women ≥40 years old, who have been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks; who have a CD4+ T-cell count ≥400 cells/mm3; and who have documented CVD or who are at increased CVD risk.

410-955-2898

Categories

Location
Topic

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More